Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383(7):650–63.
2. Sun S, Yu F, Xu D, et al. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy. BBA Rev Cancer. 2022. https://doi.org/10.1016/j.bbcan.2022.188700.
3. Izutsu K, Makita S, Nosaka K, et al. An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia/lymphoma. Blood. 2022. https://doi.org/10.1182/blood.2022016862.
4. Kusumoto S, Izutsu K, Maruyama D, et al. First-in-human study of the EZH and EZH2 dual inhibitor valemetostat tosylate (DS-3201B) in patients with relapsed or refractory non-Hodgkin lymphomas [abstract no. S218]. In: 26th Congress of the European Haematology Association. 2021.
5. Yamagishi M, Hori M, Fujikawa D, et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 2019;29(8):2321-37.e7.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献